NANOMEDICINE RESEARCH CORE (NRC)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 摘要： 纳米医学研究活动(NRA)是RCMI计划先前资助的药物传递活动的延伸成果。在过去的几年里，FAMU药学院的药物输送和药剂学领域有了显著的增长。药物输送活动的目标和使命是向FAMU的科学界提供必要的支持，使其在定向药物输送方面脱颖而出。目前，我们已经在药物输送领域建立了基本基础设施，这项活动的未来方向是通过特别侧重于纳米颗粒领域来发展新兴纳米医学领域的专业知识。这项活动的长期目标是在纳米颗粒技术领域建立资源和专业知识，可以应用于各种退行性疾病的成像，如阿尔茨海默氏症和中风，并针对癌症和慢性疲劳综合征等疾病状态的各种受体。这项活动的具体目标是：具体目标1：通过雇用关键人员和设备，为纳米药物输送研究建立适当的基础设施。具体目标2：发展具有基础科学和临床背景的研究人员之间的合作，以开发可从工作台转换到床边的创新药物输送技术。具体目标3：为药物和制剂的生物制药和药代动力学评价开发资源和专门知识。具体目标4：为少数群体科学家在纳米颗粒配方和交付领域的培训提供机会。这些能力将加强基础设施，并使佛罗里达农工大学等历史上的黑人机构的调查人员能够吸引R系列拨款等校外资金。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ABSTRACT: Nanomedicine Research Activity (NRA) is an extended outcome of the previously funded Drug Delivery Activity by the RCMI program. The last several years have seen significant growth in the drug delivery and pharmaceutics area at the College of Pharmacy, FAMU. The objective and mission of the drug delivery activity has been to give the scientific community at FAMU the requisite support to excel in targeted drug delivery. Currently, we have established basic infrastructure in the area of drug delivery and the future direction of this activity is to develop expertise in the emerging area of Nanomedicine by focusing specifically in the area of nanoparticles. The Long-term goal of this activity is to establish resources and expertise in the area of nanoparticle technology which could be applied to imaging of various degenerative diseases like Alzheimer and stroke and also to target various receptors in disease states like cancer and chronic fatigue syndrome. The specific aims of this activity are: Specific Aim 1: Establish suitable infrastructure for nanoparticle drug delivery research by hiring key personnel and equipment. Specific Aim 2: To develop collaborations between research investigators with basic science and clinical backgrounds to develop innovative drug delivery technologies which can be translated from bench to bedside. Specific Aim 3: To develop resources and expertise for biopharmaceutical and pharmacokinetic evaluation of drugs and formulations. Specific Aim 4: Provide opportunities for the training of minority scientists in the area of nanoparticle formulation and delivery. These capabilities will strengthen the infrastructure and enable the investigators at historically black institutions like Florida A&M University to be able to attract extra-mural funding like R-series grants.